Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Repetitive transcranial magnetic stimulation
10 evidence topics · 10 sources
CANMAT guideline: rTMS and theta burst protocols
“Repetitive TMS shows efficacy for DTD, with response rates of 40% to 50%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“High-frequency (5 Hz or higher) rTMS delivered over the left dorsolateral prefrontal cortex (DLPFC) has the largest evidence base and is recommended as a first-line protocol, along with low-frequency (1 Hz or lower) rTMS delivered over the right DLPFC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TBS is recommended as a first-line protocol” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Accelerated iTBS to the left DLPFC has evidence for efficacy and a large RCT found no significant differences between accelerated bilateral TBS and high frequency rTMS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unlike ECT, rTMS does not require anaesthesia and has no cognitive side effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, except in emergent situations as mentioned above, rTMS should generally be considered before ECT, given its less invasive nature and that individuals may continue to work or attend school while undergoing rTMS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
VA/DoD guideline: rTMS after two or more pharmacologic trials
NICE interventional procedures guidance on rTMS
Pivotal sham-controlled trial of left prefrontal TMS
“In a double-blind, multisite study, 301 medication-free patients with major depression who had not benefited from prior treatment were randomized to active (n = 155) or sham TMS (n = 146) conditions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Remission rates were approximately twofold higher with active TMS at week 6 and significant on the MADRS and HAMD24 scales (but not the HAMD17 scale).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Active TMS was well tolerated with a low dropout rate for adverse events (4.5%) that were generally mild and limited to transient scalp discomfort or pain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
OPT-TMS: sham-controlled trial in antidepressant-free outpatients
“Primary efficacy analysis revealed a significant effect of treatment on the proportion of remitters (14.1% active rTMS and 5.1% sham) (P = .02).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The number needed to treat was 12. Most remitters had low antidepressant treatment resistance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
THREE-D: intermittent theta burst compared with 10 Hz rTMS
“Intermittent theta burst stimulation (iTBS) is a newer form of rTMS that can be delivered in 3 min, versus 37·5 min for a standard 10 Hz treatment session.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between Sept 3, 2013, and Oct 3, 2016, we randomly allocated 205 participants to receive 10 Hz rTMS and 209 participants to receive iTBS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with treatment-resistant depression, iTBS was non-inferior to 10 Hz rTMS for the treatment of depression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common treatment-related adverse event was headache in both groups (10 Hz rTMS: 131 [64%] of 204; iTBS: 136 [65%] of 208).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis of non-surgical brain stimulation
“113 trials (262 treatment arms) that randomised 6750 patients (mean age 47.9 years; 59% women) with major depressive disorder or bipolar depression met the inclusion criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“low frequency right rTMS (3.65, 2.13 to 6.24), intermittent theta burst stimulation (3.20, 1.45 to 7.08), high frequency left rTMS (3.17, 2.29 to 4.37)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All treatment strategies were at least as acceptable as sham therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Stanford neuromodulation therapy: FDA clearance
Stanford neuromodulation therapy: initial sham-controlled trial
“The authors addressed these limitations by developing a neuroscience-informed accelerated iTBS protocol, Stanford neuromodulation therapy (SNT; previously referred to as Stanford accelerated intelligent neuromodulation therapy, or SAINT).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At the planned interim analysis, 32 participants with treatment-resistant depression had been enrolled, and 29 participants who continued to meet inclusion criteria received either active (N=14) or sham (N=15) SNT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean percent reduction from baseline in MADRS score 4 weeks after treatment was 52.5% in the active treatment group and 11.1% in the sham treatment group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Stanford neuromodulation therapy: confirmatory sham-controlled trial
“In the current RCT, 53 participants with TRD were enrolled, and 48 who continued to meet entry criteria were randomized to receive active (N=24) or sham (N=24) SNT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 1-month, remission (primary outcome) was achieved in 50.0% of active vs. 20.8% of sham participants” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote